Generic Name
Ibandronate
FDA approval date: March 19, 2012
Classification: Bisphosphonate
Form: Injection, Tablet
What is Ibandronate?
Ibandronate sodium tablet is a bisphosphonate indicated for the treatment and prevention of postmenopausal osteoporosis.
Approved To Treat
Top Global Experts
Save this treatment for later
Not sure about your diagnosis?
Related Clinical Trials
Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women: A Randomized Control Trial
Summary: This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly. BTMs may show a response to medication within just 3 to 6 mo...
Changes of Bone Turnover Markers and Bone Mineral Density After Treatment in Osteoporotic Patients
Summary: To examine the changes of bone mineral density and bone turnover markers after Bonviva treatment in osteoporotic patients